Electroencephelographs (EEG) Pipeline Insight and Competitive Landscape Report 2022: Comprehensive Insights About 20+ Companies and 20+ Pipeline Devices - ResearchAndMarkets.com

The "Electroencephelographs (EEG)-Pipeline Insight and Competitive Landscape, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Electroencephelographs (EEG)-Pipeline Insight and 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape.

Increased incidence of disorders like Alzheimer's disease, epilepsy, Dementia, Multiple Sclerosis, Parkinson's disease, and stroke around the world has been crucial to elevate the use of electroencephalography (EEG) products. Growing prevalence of neurological diseases and increasing awareness about these are significant contributing factors to advancement.

Hence, the market is expected to growth in the coming years. The industries invest in R&D to upgrade existing products and create new ones to satisfy the rising demand for specialized equipment, which is the major reason for an extensive pipeline in this segment.

This report provides a detailed study of the emerging Electroencephelographs devices along with competitive landscape to help better understand the emerging Electroencephelographs devices.

Electroencephelographs Devices Competitive Assessment

This segment of the Electroencephelographs report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates and the latest news and press releases. The report also provides list of major players involved in the pipeline product development.

Product Type

Electroencephelographs can divided based on Types - Standalone devices and Portable devices- both are covered in this report.

Product Channels

Electroencephelographs can be divided based on Channels - 8-channel EEG, 21-channel EEG, 25 channel EEG, 32-channel EEG, 40-channel EEG, Multi-channel EEG.

Major Players in Electroencephelographs

There are approx. 20+ key companies which are developing the products for Electroencephelographs.

Cerora Borealis: Cerora

The Cerora Borealis medical device platform is subject to FDA review and designed to measure and record brainwave activity (EEG) as well as other biosensor data, including cognitive data and voice-based data streams. The platform provides state of the art, mobile and versatile multimodal biosensor data. The first release is intended as an adjunct to standard clinical practice to aid in the evaluation of subject's medical or psychological state. Cerora's next generation devices are intended to aid in the diagnosis and management of various brain disorders, injuries, and diseases. The first release of Borealis is estimated to ship into US markets in 2021 at the earliest.

Circaid EEG: Circadian Therapeutics

Circaid EEG is being developed by Circadian Therapeutics. Its proof of concept study has already being done and prototype dev phase is ongoing. In a controlled clinical evaluation, data obtained using Circaid EEG correlate highly with those derived from traditional PSG recording equipment. Work continues towards CE marking and US 510(k) approval.

Electroencephelographs (EEG) Competitive Benchmarking

This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.

The analysis is based on

• Brand Positioning of Leading companies
• Application
• Industry Collaborations

Electroencephelographs (EEG): Commercialization Activity

This segment of the report provides a detailed list of any commercial activity in the field of EEG devices ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Development Activities

• In June 2020 a study investigating EEG microstate dynamics in schizophrenia was the first research on the temporal structure of the four canonical EEG microstates of schizophrenic patient siblings. Results indicate that a possible endophenotype for schizophrenia is the dynamics of resting-state EEG microstats, specifically classes C and D.
• In April 2020, Marking a major milestone on the path to meeting the objectives of the NIH BRAIN initiative, researchers developed advanced high-density electroencephalography (EEG) as the future paradigm for dynamic functional neuroimaging. The study also marks one of the first times high-density EEG has been used to study epileptic seizures. The more powerful imaging technology, packing more than double the electrodes generally used in a clinical setting, is now available to patients treated at the Mayo Clinic.

Key Questions Answered

• What are significant companies in this segment, their information, analysis, and insights to improve R&D strategies?
• How to identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage?
• What are important and diverse types of Electroencephelographs under development?
• What are market-entry and market expansion strategies in Electroencephelographs?
• What are some of the mergers and acquisitions and to identify major players with the most promising pipeline?
• What is in-depth analysis of the product's current stage of development, territory and estimated launch date?

Key Players

• AAT Medical Ltd
• Advanced Medical Electronics Corp
• Advanced neurometrics inc.
• Belluscura Limited
• BioSignal Analytics Inc
• Bio-Signal Group Corp.
• Bittium Biosignals Ltd
• BrainCare OY'
• BrainScope Company Inc
• Cerora Inc
• Circadian Therapeutics
• Cognionics, Inc.
• Cogwear LLC
• Compumedics Ltd
• Electrical Geodesics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/cyc6uk

View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005611/en/